Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis
| Autor: | M. A. Cremer, Linda K. Myers, Andrew H. Kang, Laura D Carbone, Grant W. Somes, Juan Bustillo, Elaine Steere, Stanley B. Kaplan, Kristine M. Lohr, Gurjit Kaeley, Miguel González, Arnold E. Postlethwaite, Jacob A. Aelion, Jerome M. Seyer, Kevin McKown |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Immunology Arthritis medicine.disease Placebo Rheumatology Surgery Clinical trial Oral administration Rheumatoid arthritis Internal medicine Immunopathology Immunology and Allergy Medicine Pharmacology (medical) skin and connective tissue diseases business |
| Zdroj: | Arthritis & Rheumatism. 42:1204-1208 |
| ISSN: | 1529-0131 0004-3591 |
| Popis: | Objective To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebo-controlled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text